Expert Opinion on Emerging Drugs,
Journal Year:
2024,
Volume and Issue:
29(3), P. 233 - 249
Published: April 25, 2024
Introduction
Atopic
dermatitis
(AD)
is
an
inflammatory
skin
condition
that
affects
millions
of
pediatric
and
adult
patients
with
well-studied
impact
on
morbidity
quality
life.
Management
occurs
in
a
stepwise
fashion
beginning
preventative
measures
before
immunomodulators
are
introduced.
However,
challenges
remain
treatment
moderate
to
severe
atopic
refractory
first
second-line
treatments
there
only
few
topical
anti-inflammatory
options,
especially
for
patients.
Balkan Medical Journal,
Journal Year:
2024,
Volume and Issue:
unknown, P. 239 - 247
Published: July 5, 2024
Atopic
dermatitis
(AD)
is
a
chronic
inflammatory
condition
that
significantly
affects
the
quality
of
life
both
patients
and
their
families
or
caregivers.
Recently,
treatment
for
moderate-to-severe
AD
were
limited
to
conventional
immunosuppressive
therapies.
However,
currently,
with
approval
biologic
treatments
oral
small
molecules
in
past
decade,
effective
safe
management
possible.
Despite
these
advancements,
challenges
unmet
needs
clinical
practice
remain.
This
includes
who
do
not
respond
well
cannot
tolerate
existing
options
inadequate
therapies
can
modify
disease
course.
review
aimed
provide
an
overview
current
approach
AD,
highlight
treatment,
discuss
rationale
novel
emerging
evidence
on
systemic
AD.
Journal of Allergy and Clinical Immunology,
Journal Year:
2023,
Volume and Issue:
152(4), P. 927 - 932
Published: July 13, 2023
Therapies
specifically
targeting
nonhistaminergic
pruritus
are
largely
lacking.
Difelikefalin
(DFK)
has
been
found
to
reduce
itch
in
various
chronic
pruritic
conditions,
including
atopic
dermatitis
(AD).
Frontiers in Pharmacology,
Journal Year:
2024,
Volume and Issue:
15
Published: Dec. 6, 2024
Background
and
Objective
Uremic
pruritus
is
a
persistent
condition
that
difficult
to
cure
in
patients
with
end-stage
renal
disease
who
are
having
regular
dialysis.
It
highly
prevalent,
current
therapies
have
limited
effectiveness
can
cause
significant
adverse
effects.
Several
trials
provided
evidence
difelikefalin
be
an
effective
treatment
for
uremic
pruritus,
few
side
responses.
However,
it
important
note
the
available
limited.
This
study
collected
published
randomized
controlled
systematic
review
Meta-analysis,
explore
efficacy
safety
of
treating
provide
evidence-based
medical
clinical
treatment.
Methods
A
literature
search
was
conducted
PubMed,
EMBASE,
Web
Science,
Cochrane
Library
Data
from
building
libraries
6
January
2024.
We
extracted
data
eligible
studies
analyze
hemodialysis
pruritus.
Results
comprised
9
4,118
people.
The
meta-analysis
demonstrated
more
than
placebo
Specifically,
resulted
greater
improvement
WI-NRS
scores
at
least
3
points
baseline
(OR
=
1.98)
4
1.94).
Additionally,
led
decrease
total
score
5-D
itch
scale
(MD
1.56),
skindex-10
4.92),
0.91).
Conclusion
Difelikefalin
demonstrates
alleviating
individuals
suffering
uremia.
Althogh
has
events,
they
mild.
Skin Health and Disease,
Journal Year:
2024,
Volume and Issue:
4(4)
Published: May 5, 2024
Patients
with
atopic
dermatitis
(AD)
exhibit
heterogeneous
clinical
phenotypes,
reflecting
different
combinations
of
itch
and
lesional
severity.
AD
severe
but
clear-moderate
lesions,
also
known
as
itch-dominant
AD,
is
a
common
phenotype.
Frontiers in Nephrology,
Journal Year:
2024,
Volume and Issue:
4
Published: July 30, 2024
The
objective
of
this
study
is
to
investigate
the
effects
oral
supplementation
with
eicosapentaenoic
acid
(EPA)
on
circulating
inflammatory
factors,
cardiometabolic
parameters,
skin
moisturization,
and
consequent
symptoms
pruritus
depression
in
maintenance
hemodialysis
patients.
